All In Biotech

Drug Trial Radar · NCT05949333

Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy

Reducing Neutropenia Incidence by Changing the Date of Eflapegrastim Administration in Breast Cancer Patients Who Have Experienced Neutropenia After Chemotherapy

Last checked: Nov 20, 2026Latest source record: Feb 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

100

Planned (sponsor's estimate)

Start

Nov 7, 2023

Primary completion

Jan 2025

Study completion Jul 2025

Sponsor

Lead sponsor
Eunseong Medical Foundation Good GANG-AN HOSPITALAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Hanmi Pharmaceutical Company Limited
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who experienced neutropenia after receiving pegfilgrastim on day 1 of the first round are randomly assigned to either the control or experimental arm. Patients in the control arm continue pegfilgrastim injection on day 1 while patients in the experimental arm will receive pegfilgrastim injection on day 3 to see if changing the pegfilgrastim administration date from day 1 to day 3 starting from the second round of chemotherapy could reduce the incidence of neutropenia

Conditions

  • Breast Neoplasms

Interventions

  • EflapegrastimDrug

    long-acting granulocyte-colony stimulating factor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rate of severe neutropenia Incidence rate of severe neutropeniaTime frame: cycle 2-5 (21 days for each cycle), 105 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Good Gang-An Hospital

    Busan, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.